Stability and compatibility of granisetron hydrochloride in i.v. solutions and oral liquids and during simulated Y-site injection with selected drugs

American Journal of Health-System Pharmacy

Volumn 53, Issue 3, 1996, Pages 294-304

  Mayron, David ^a   Gennaro, Alfonso R ^b  

^a Mayron Research Laboratories Inc   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Additives; Antiemetics; Antineoplastic agents; Diluents; Doxorubicin hydrochloride; Drug administration routes; Granisetron hydrochloride; Incompatibilities; Injections; Liquids; Stability

Indexed keywords

BICARBONATE; CARBOPLATIN; CEFTAZIDIME; CHLORMETHINE; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GENTAMICIN; GRANISETRON; HYDROMORPHONE; IFOSFAMIDE; LORAZEPAM; MAGNESIUM SULFATE; MESNA; METHOTREXATE; MEZLOCILLIN; MORPHINE SULFATE; PACLITAXEL; POTASSIUM CHLORIDE; STREPTOZOCIN; TIMENTIN; VINCRISTINE;

ANTIEMETIC ACTIVITY; ARTICLE; DRUG DETERMINATION; DRUG FORMULATION; DRUG MIXTURE; DRUG STABILITY; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL;

EID: 0030061530     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.3.294     Document Type: Article

References (29)

1. 3-receptor antagonists. Hosp Formul. 1994; 29(Suppl 5):S4-9.
2. Navari RM, Kaplan HG, Gralla RJ et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994; 12:2204-10.
3. Kytril (granisetron hydrochloride) injection prescribing information. Philadelphia: SmithKline Beecham Pharmaceuticals. 1994 Feb.
4. Pinguet F, Rouanet P, Martel P et al. Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions. J Pharm Sci. 1995; 84:267-8. Letter.
5. Trissel LA, Martinez JF. Compatibility of granisetron hydrochloride with selected alkaline drugs. Am J Health-Syst Pharm. 1995; 52:208. Letter.
6. Allen LV Jr, Stiles ML. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Part 2. Am J Hosp Pharm. 1981; 38:380-1.
7. Allen LV Jr, Levinson RS, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm. 1977; 34:939-43.
8. Adolphe AB, Glasofer ED, Troetel WM et al. Preliminary pharmacokinetics of streptozotocin, an antineoplastic antibiotic. J Clin Pharmacol. 1977; 17:379-88.
9. Allsopp MA, Sewell GJ, Rowland CG et al. The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles. Int J Pharm. 1991; 69:197-210.
10. Barthes DMC, Rochard EB, Pouliquen IJ et al. Stability and compatibility of etoposide in 0.9% sodium chloride injection in three containers. Am J Hosp Pharm. 1994; 51:2706-9.
11. Cheung Y-W, Cradock JC, Vishnuvajjala BR et al. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm. 1987; 44:124-30.
12. Chin A, Ramakrishnan RR, Yoshimura NN et al. Paclitaxel stability and compatibility in polyolefin containers. Ann Pharmacother. 1994; 28:35-6.
13. Hagan RL. High-performance Liquid chromatography for small-scale studies of drug stability. Am J Hasp Pharm. 1994; 51:2162-75.
14. Huber L, ed. Good laboratory practice: a primer for high-performance liquid chromatography, capillary electrophoresis, and UV-visible spectroscopy. Valley Forge, PA: Hewlett-Packard, 1993; publication no. 12-5091-6259E.
15. Inagaki K, Gill MA, Okamoto MP et al. Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration. Am J Hosp Pharm. 1992; 49:2769-72.
16. James CA, Rogers HJ. Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1986; 382:394-8.
17. Kirk B. Stability of reconstituted mustine injection BP during storage. Br J Parenter Ther. 1986; 7:86-7,90-2.
18. Sewell GJ, Riley CM, Rowland CG. The stability of carboplatin in ambulatory continuous infusion regimes. J Clin Pharm Ther. 1987; 12:427-32.
19. Sidau B, Shaw IC. Determination of sodium 2-mercaptoethanesulphonate by high-performance liquid chromatography using post-column reaction colorimetry or electrochemical detection. J Chromatogr. 1984; 311:234-8.
20. Theuer VH, Scherbel G, Distler F et al. Cisplatin-Injektionslosung: Stabilitat einer in der Krankenhausapotheke aseptisch hergestellten IV Injektionslösung. Krankenhauspharmazie. 1990; 11:288-91.
21. Trissel LA, Flora KP. Stability studies: five years later. Am J Hosp Pharm. 1988; 45:1569-71.
22. Trissel LA, Xu Q Martinez JF et al. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22, and 32 °C Am J Hasp Pharm. 1994; 51:2138-42.
23. The United States Pharmacopeia, 23rd rev., and The National Formulary, 18th ed. Rockville, MD: The United States Pharmacopoeial Convention; 1994.
24. The United States Pharmacopeia, 22nd rev., and The National Formulary, 17th ed. Rockville, MD: The United States Pharmacopoeial Convention; 1989.
25. Vigevani A, Williamson MJ, Doxorubicin. In: Florey K, ed. Analytical profiles of drug substances. Vol. 9. New York: Academic Press; 1980:245-74.
26. Waugh WN, Trissel LA, Stella VJ. Stability, compatibility, and plastlcizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm. 1991; 48:1520-4.
27. Jarosinski PF, Hirschfeld S. Precipitation of ondansetron in alkaline solutions. N Engl J Med. 1991; 325:1315-6. Letter.
28. Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1991; 48:988-92.
29. Fox J, Ikeda M. Precipitation of ondansetron in alkaline solutions. N Engl J Med. 1991; 325:1315-6. Letter.